Clinical Trial Update: A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab as consolidation therapy after radical chemoradiotherapy in locally advanced unresectable esophageal squamous cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN